Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of April 14, 2025 in Intellia Therapeutics, Inc. Lawsuit - NTLA
Portfolio Pulse from
Levi & Korsinsky law firm is pursuing a class action securities lawsuit against Intellia Therapeutics, alleging securities fraud between July 30, 2024 and January 8, 2025. The lawsuit claims the company misled investors about its NTLA-3001 study for alpha-1 antitrypsin deficiency, failing to disclose declining demand for viral-based editing. On January 9, 2025, Intellia announced halting the NTLA-3001 research and reducing workforce by 27%, causing its stock price to drop from $12.02 to $10.20.
April 10, 2025 | 11:45 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Intellia Therapeutics is facing a class action lawsuit alleging securities fraud, which could negatively impact investor confidence and stock performance.
The lawsuit and program discontinuation directly impact Intellia Therapeutics, suggesting potential negative short-term stock performance due to legal risks and reduced investor trust.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100